At the 2019 ATS conference in Dallas, TX, USA, Nick Hanania (Baylor College of Medicine, Houston, TX, USA), discusses unmet needs in the management of patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) at risk of exacerbations; the budesonide/formoterol fumarate metered dose inhaler (BFF MDI) and how it differs from other COPD inhaled corticosteroid/bronchodilator combination; and the impact of BFF MDI on patients with COPD assessed in the SOPHOS study.
Questions
1. What unmet needs currently exist in the management of patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) at risk of exacerbations? (0:04)
2. Please briefly describe the budesonide/formoterol fumarate metered dose inhaler (BFF MDI) and how it differs from other COPD inhaled corticosteroid/bronchodilator combinations. (0:56)
3. How was the impact of BFF MDI on patients with COPD assessed in the SOPHOS study? (1:52)
4. Briefly outline the main findings of the SOPHOS study. (2:57)
5. What implications do these results have for COPD management? (4:22)
Speaker disclosure: Nick Hanania has nothing to disclose in relation to this video interview.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at ATS 2019, Dallas, TX, USA, May 2019.
